IPO News | JunSai Bio plans to list on the Hong Kong stock exchange; China Securities Regulatory Commission requests supplementary explanations regarding the pricing and valuation basis of previous capital increases and equity transfers.

JunSai Bio plans to list on the Hong Kong stock exchange, and the China Securities Regulatory Commission has requested supplementary explanations regarding the pricing and valuation basis of previous capital increases and equity transfers.

Zhitong FinanceMar 2 20:23

At a Glance: March's Hottest IPOs - Shangmi Technology Approved! Four New Stocks, Including ZhaoWei Electromechanical and EastControl, Undergoing Enthusiastic Subscription.

Hello, fellow investors! The New Stock Observer is here to provide updates on the popular HK IPOs in March and throughout 2026. Fellow investors, check it out now!

Futu NewsFeb 28 09:55

IPO News | New Life Pharmaceuticals, Winged Robot Technology, and others have received material acceptance from the China Securities Regulatory Commission for their proposed Hong Kong IPOs.

New Ji Pharmaceutical, Yi Fei Technology, and others have had their materials for a proposed Hong Kong IPO received by the China Securities Regulatory Commission.

Zhitong FinanceJan 30 20:24

At a Glance: January's Hottest IPOs: First of the New Year! Biren Technology listed on the Hong Kong Stock Exchange on January 2nd, with 10 new stocks including Zhipu, MINIMAX, and TianShuZhiXin in active subscription.

Hello, fellow investors! The Futu IPO Assistant is here to provide you with the most popular IPOs in HK for January and 2026. Fellow investors, come and check them out!

Futu NewsDec 31, 2025 15:57

JunSai Bio: Focusing on the breakthrough of 'lymphodepletion-free' solid tumor therapy, GC101 is expected to submit an application for market approval in 2026.

Sina Tech News, December 30th, in the morning: Shanghai JunCell Biotechnology Co., Ltd. (hereinafter referred to as "JunCell Bio"), which focuses on innovative cell therapies and novel drug development for solid tumors, has officially submitted its prospectus to the Hong Kong Stock Exchange, planning to list on the biotechnology sector under Chapter 18A of the Hong Kong listing rules. According to reports, JunCell Bio's TIL (Tumor-Infiltrating Lymphocyte) therapy GC101 is the world’s first treatment that does not require high-intensity lymphodepletion chemotherapy or IL-2 (Interleukin-2, a cytokine that promotes T-cell growth, differentiation, and survival) administration. Additionally, GC20 represents the world’s first non-viral vector genetically modified TIL cell-based new drug.

Sina TechnologyDec 30, 2025 10:41

JunSai Bio-B has filed its IPO prospectus and plans to go public in Hong Kong, with CITIC Securities as the sole sponsor.

JunSai Bio-B has filed its IPO prospectus and plans to go public in Hong Kong, with CITIC Securities as the sole sponsor.

Ryanben CapitalDec 11, 2025 14:46